The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

April 6, 2012 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Meeting in November. [Editor’s note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
Explore This Issue
April 2012
Also By This Author
  • Making of the Guidelines

Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis (RA), vasculitis, and Behçet’s disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rituximab for ANCA-Associated Vasculitis

John H. Stone, MD, MPH, director of clinical rheumatology at Massachusetts General Hospital in Boston, focused on results from the RAVE trial, which is evaluating rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Traditionally, cyclophosphamide and glucocorticoids have been the mainstay of treatment for these patients. Results published in 2010 focused on six-month results from the RAVE trial and showed that rituximab was not inferior to cyclophosphamide (CYC) for remission induction.1 Dr. Stone’s presentation focused on six to 18 months of follow-up data from the RAVE trial.

Nearly 200 patients with severe Wegener’s granulomatosis or microscopic polyangiitis, all of whom were ANCA positive, received one to three pulses of methylprednisolone. The patients were then randomized to receive rituximab infusions and CYC placebo for three to six months or rituximab placebo infusions and CYC for three to six months. After six months, the two randomized groups received a placebo for 12 to 15 months or azathioprine for 12 to 15 months.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Let me emphasize, for 12 to 15 months, following the six-month outcome, patients in the rituximab group were on no medication after they were tapered off prednisone,” Dr. Stone said.

Investigators found that a single course of rituximab was just as effective as 18 months of CYC and azathioprine. “Relapses were more common in patients who were PR3-ANCA positive, had Wegener’s, and had relapsing disease at baseline,” Dr. Stone said. The risk for severe flare with rituximab appears low as long as B cells remain depleted and ANCA remains negative, Dr. Stone said.

“We hope ongoing mechanistic studies will enable us to predict who’s at risk for disease flare and when that disease will occur,” he said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

JAK2 in Systemic Sclerosis

Janus kinase 2 (JAK2) inhibitors can serve as a possible treatment for fibrotic diseases, said Clara Dees, PhD, a researcher in the department of medicine 3, rheumatology and immunology, at the University of Erlangen in Nuremberg, Germany. She explained that activated JAK2 is implicated in myeloproliferative diseases and that JAK2 inhibitors are currently under evaluation in clinical trials.

Dr. Dees is involved in the study of JAK2 signaling in active systemic sclerosis patients. This research has found that JAK2 signaling is indeed active in these patients and reduces collagen expression. “JAK2 is persistently active in fibroblasts. Inhibition of JAK2 reduces the intrinsic activation of systemic sclerosis fibroblasts,” Dr. Dees said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis, Scleroderma, Vasculitis Tagged With: ACR/ARHP Annual Meeting, JAK inhibitors, janus kinase, RA, Research, Rheumatoid arthritis, rituximab, Scleroderma, sclerosis, Treatment, VasculitisIssue: April 2012

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)